In multiple myeloma (MM), insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) stabilizes the expression of a cell surface glycoprotein CD44 that is involved in drug resistance of MM cells. This evidence concerns the gene IGF2BP3 and AL amyloidosis.